Lab-on-a-Chip Platforms for Detection of Cardiovascular Disease and Cancer Biomarkers
1
Department of Physics and Astronomy, University of Manitoba, Winnipeg, MB, R3T 2N2, Canada
2
Institute of Applied Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230088, China
3
Victoria General Hospital and River Heights/Fort Garry Community Areas, Winnipeg, MB, R3T 2E8, Canada
4
Seven Oaks General Hospital, Winnipeg, MB, R2V 3M3, Canada
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally.
Sensors 2017, 17(12), 2934; https://doi.org/10.3390/s17122934
Received: 28 October 2017
/
Revised: 30 November 2017
/
Accepted: 13 December 2017
/
Published: 17 December 2017
(This article belongs to the Special Issue Sensors for Health Monitoring and Disease Diagnosis)
Cardiovascular disease (CVD) and cancer are two leading causes of death worldwide. CVD and cancer share risk factors such as obesity and diabetes mellitus and have common diagnostic biomarkers such as interleukin-6 and C-reactive protein. Thus, timely and accurate diagnosis of these two correlated diseases is of high interest to both the research and healthcare communities. Most conventional methods for CVD and cancer biomarker detection such as microwell plate-based immunoassay and polymerase chain reaction often suffer from high costs, low test speeds, and complicated procedures. Recently, lab-on-a-chip (LoC)-based platforms have been increasingly developed for CVD and cancer biomarker sensing and analysis using various molecular and cell-based diagnostic biomarkers. These new platforms not only enable better sample preparation, chemical manipulation and reaction, high-throughput and portability, but also provide attractive features such as label-free detection and improved sensitivity due to the integration of various novel detection techniques. These features effectively improve the diagnostic test speed and simplify the detection procedure. In addition, microfluidic cell assays and organ-on-chip models offer new potential approaches for CVD and cancer diagnosis. Here we provide a mini-review focusing on recent development of LoC-based methods for CVD and cancer diagnostic biomarker measurements, and our perspectives of the challenges, opportunities and future directions.
View Full-Text
Keywords:
lab-on-a-chip; cardiovascular disease; cancer; biomarker; microfluidic; point-of-care
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Wu, J.; Dong, M.; Santos, S.; Rigatto, C.; Liu, Y.; Lin, F. Lab-on-a-Chip Platforms for Detection of Cardiovascular Disease and Cancer Biomarkers. Sensors 2017, 17, 2934. https://doi.org/10.3390/s17122934
AMA Style
Wu J, Dong M, Santos S, Rigatto C, Liu Y, Lin F. Lab-on-a-Chip Platforms for Detection of Cardiovascular Disease and Cancer Biomarkers. Sensors. 2017; 17(12):2934. https://doi.org/10.3390/s17122934
Chicago/Turabian StyleWu, Jiandong, Meili Dong, Susy Santos, Claudio Rigatto, Yong Liu, and Francis Lin. 2017. "Lab-on-a-Chip Platforms for Detection of Cardiovascular Disease and Cancer Biomarkers" Sensors 17, no. 12: 2934. https://doi.org/10.3390/s17122934
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
